The 2026 Eli Lilly lawsuits cover severe stomach, intestinal, and sudden vision-loss injuries linked to Mounjaro/Zepbound and Trulicity. Eligibility turns on Lilly-drug use plus a matching diagnosis, backed by pharmacy and medical records, with state filing deadlines applying. Multidistrict litigation, or MDL, moves many similar federal cases to one judge for shared pretrial work. The Lilly-related claims follow two federal tracks, one for gut injuries and a smaller one for vision loss.
Official resources:
- Read the official notice from Uscourts — Use this primary source to verify the official announcement.
- Read the official guidance from NIH — Use this primary source to verify the official guidance.
Table of Contents
- Who may qualify?
- Where are federal cases now?
- What proof matters most?
- What do drug labels and regulators say?
- When should you act?
Who may qualify?
Patients prescribed tirzepatide as Mounjaro or Zepbound, or dulaglutide as Trulicity, fit the core group when a later diagnosis matches. According to the King Law October 2026 update, qualifying injuries include gastroparesis, intestinal obstruction or ileus, and NAION sudden vision loss (King Law drug-injury summary).
Check these three points together: Gastroparesis means the stomach empties too slowly. Ileus means the intestine temporarily stops moving. NAION means blood flow loss injures the optic nerve.
- Lilly prescription for Mounjaro/Zepbound or Trulicity
- Later diagnosis of delayed stomach emptying, bowel blockage, or sudden optic-nerve vision loss
- Medical timeline linking drug use before the injury diagnosis
Where are federal cases now?
Federal gut-injury suits over GLP-1 drugs, including Mounjaro/Zepbound and Trulicity, are consolidated as MDL No. 3094 in the Eastern District of Pennsylvania before Judge Karen Spencer Marston, according to the court's MDL case page. The gut-injury track is far larger and more mature than the vision-loss track.
Motley Rice reported about 4,022 pending gut cases in September 2026, compared with 216 vision-loss cases (September 2026 litigation update). Federal NAION vision-loss claims were separately centralized in December 2025 as MDL No. 3163, also before Judge Marston. That track covers both Novo Nordisk semaglutide drugs and Lilly tirzepatide drugs.
What proof matters most?
Useful proof starts with pharmacy and prescription records showing Lilly-drug use. Add medical records showing the injury, including gastroparesis diagnosis, gastric-emptying study, obstruction imaging, or eye-doctor NAION diagnosis. Request records from each place separately because pharmacies, clinics, hospitals, and eye doctors often store them apart.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
Keep the original bottles, labels, and appointment notices when available. Write down when symptoms began, when care was sought, and when work or daily tasks changed. A short timeline helps connect prescription dates, dose changes, emergency visits, tests, and diagnosis. Missing months make review slower, so fill gaps before memories fade.
What do drug labels and regulators say?
Mounjaro's FDA-approved label states that use is associated with sometimes-severe gut reactions and that it was not studied in severe gut disease including severe gastroparesis, so it is not recommended there. That language matters because prior severe stomach disease may weaken a claim.
Europe's regulator concluded in June 2025 that NAION is a very rare semaglutide side effect affecting up to 1 in 10,000 users and said stop semaglutide if NAION is confirmed, according to the European Medicines Agency's June 2025 safety conclusion. The vision-loss evidence is uneven across brands. The strongest published NAION signal involves Novo Nordisk semaglutide, with a 2024 Harvard/Mass Eye and Ear study finding higher relative risk but very low absolute risk; evidence for Lilly tirzepatide is weaker.
When should you act?
There is no single claim deadline. State personal-injury limits typically run one to three years from injury or discovery, with Texas generally allowing two years.
The MDL set Aug. 7, 2026 for key causation and summary-judgment rulings, so early filing preserves rights while major legal questions move forward. Ask a lawyer promptly about the deadline for the state where the injury was found, then start pharmacy and medical-record requests the same week.
You Might Also Like
- Pharmaceutical Lawsuit Settlement Guide 2026: Eligibility, Evidence, and Deadlines
- Paragard IUD Lawsuit Guide 2026: Eligibility, Evidence, and Deadlines
- Asbestos Guide 2026: Eligibility, Evidence, and Deadlines